438565-34-5

Usage

Uses

Used in Pharmaceutical Industry:
(3-BENZO[1,3]DIOXOL-5-YL-ISOXAZOL-5-YL)-METHANOL is used as a pharmaceutical compound for its reported antioxidant and anti-inflammatory properties, which may contribute to the development of new drugs targeting various health conditions.
Used in Medicinal Chemistry Research:
(3-BENZO[1,3]DIOXOL-5-YL-ISOXAZOL-5-YL)-METHANOL is used as a building block in the synthesis of more complex molecules, facilitating the creation of novel pharmaceutical agents with potential therapeutic benefits.
Used in Biological Research:
(3-BENZO[1,3]DIOXOL-5-YL-ISOXAZOL-5-YL)-METHANOL is utilized in biological research to explore its potential pharmacological activities, furthering understanding of its mechanisms of action and applications in medicine.

Upstream product

• 61946-94-9 N-hydroxy-benzo[1,3]dioxole-5-carboximidoyl chloride 
• 107-19-7 propargyl alcohol 
• 2089-36-3 piperonal oxime 
• 3162-29-6 1-(benzo[d][1,3]dioxol-6-yl)ethanone 
• 120-57-0 piperonal 
• 2089-36-3 (E)-3,4-methylenedioxybenzaldehyde oxime 

Downstream Products

• 808739-26-6 3-(benzo[d][1,3]dioxol-5-yl)isoxazole-5-carbaldehyde 
• 885273-58-5 C₁₁H₁₀N₂O₃ 
• 1337539-71-5 C₂₇H₃₁FN₄O₃ 

Relevant academic research and scientific papers

Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity

Despite the impressive scientific and technological advances of recent decades, no effective treatment is currently available for Chagas disease. Our research group has been studying the design and synthesis of analogues of natural lignans aiming to identify compounds with antiparasitic activity. This article reports the synthesis of 42 novel bis-heterocyclic derivatives and the structure-activity relationship study conducted based on results of biological assays against Trypanosoma cruzi amastigotes. Thirty-seven compounds were active, and eight of them had GI50 values lower than 100 μM (GI50 88.4–12.2 μM). A qualitative structure activity relationship study using three dimensional descriptors was carried out and showed a correlation between growth inhibitory potency and the presence of bulky hydrophobic groups located at rings A and D of the compounds. Compound 3-(3,4-dimethoxyphenyl)-5-((4-(4-pentylphenyl)-1H-1,2,3-triazol-1-yl)methyl)isoxazole (31) was the most active in the series (GI50 12.2 μM), showing, in vitro, low toxicity and potency similar to benznidazole (GI50 10.2 μM). These results suggest that this compound can be a promising scaffold for the design of new trypanocidal compounds.

Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis

Chagas disease and leishmaniasis are neglected tropical diseases (NTDs) endemic in developing countries. Although there are drugs available for their treatment, efforts on finding new efficacious therapies are continuous. The natural lignans grandisin (1)

Design and synthesis of pyrazole/isoxazole linked arylcinnamides as tubulin polymerization inhibitors and potential antiproliferative agents

As pyrazole and isoxazole based derivatives are well-known for displaying a considerable biological profile, an attempt has been made to unravel their cytotoxic potential. In this context, a number of pyrazole/isoxazole linked arylcinnamide conjugates (15

Synthesis and biological evaluation of novel T-type Ca2+ channel blockers

A small molecule library of piperazinylalkylisoxazole derivatives containing about 600 compounds was designed, synthesized and evaluated for blocking effects on T-type Ca2+ channel. Several ligands were identified to possess high inhibitory activity against the T-type Ca 2+ channel. The compound 21 with trifluoromethyl substituents at C3-position of phenyl group (R1) and C2- position of phenyl group (R2) showed the highest inhibitory activity with IC50 value of 1.02μM, which is comparable to that of mibefradil.

Synthesis of isoxazolines and isoxazoles using poly(ethylene glycol) as support

A general method for the liquid-phase syntheses of isoxazoles and isoxazolines through a 1,3-dipolar cycloaddition is described. The poly(ethylene glycol) (PEG)-supported alkyne 2 or alkene 6 reacted with nitrile oxides generated in situ from aldoximes 3, followed by cleavage from the PEG, to give isoxazoles or isoxazolines in good yield and purity.

Soluble polymer-supported synthesis of isoxazoles

The first soluble polymer-supported synthesis of isoxazoles through a 1,3-dipolar cycloaddition is described. A soluble polymer-supported alkyne reacts with nitrile oxides generated in situ to give isoxazoles in good yield.